Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768345 | 0.83 | CYP19A1 (0.49) | CDC7CDK2SLC22A12MAPTCYP19A1 | |
| SCHEMBL6896094 | 0.77 | CDC7 (0.47) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL14312995 | 0.74 | CDC7 (0.49) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL27976818 | 0.74 | CDC7 (0.45) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL18940537 | 0.74 | CDC7 (0.45) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL29497360 | 0.74 | MAPT (0.50) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL30267535 | 0.74 | CDC7 (0.45) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL10197254 | 0.74 | CDC7 (0.45) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL256341 | 0.74 | MAPT (0.50) | CDC7CDK2SLC22A12RAPGEF4MAPT | |
| SCHEMBL31609625 | 0.74 | P2RX7 (0.43) | CDC7CDK2SLC22A12RAPGEF4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017011531-A2 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CDC7 150/4885CDK2 89/4885SLC22A12 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.